You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 17 No. 4, October 1967 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (105)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Drug Therapy of Depression

Amitriptyline, Perphenazine, and Their Combination in Different Syndromes

Leo E. Hollister, MD; John E. Overall, PhD; Jack Shelton, MD; Veronica Pennington, MD; Isham Kimbell, MD; Merlin Johnson, MD

Arch Gen Psychiatry. 1967;17(4):486-493.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

RESEARCH into the nature of depression and its treatment by drugs is hobbled by the fact that depressions do not constitute a single homogeneous entity. The term "depression" is employed to refer to a symptom, a syndrome, or a diagnostic entity.1 It has been unclear whether so-called antidepressant drugs are to be regarded as specifically effective for treatment of the symptom, syndrome, or diagnostic entity. Our research has led us to the conclusion that it is important to evaluate the potential usefulness of drug treatments in distinct syndromes of depression.

In our series of studies, we began by comparing the therapeutic efficacy of antidepressant drugs among heterogeneous groups of patients whose presenting symptom was predominantly depression of mood. Although it was possible to demonstrate a significant average difference in therapeutic response between a tricyclic antidepressant, imipramine, and placebo, the difference was not striking.2 A subsequent study, which . . . [Full Text PDF of this Article]


Author Affiliations

Palo Alto, Calif; Galveston, Tex; Palo Alto, Calif; Jackson, Miss; Houston; Seattle

From the Veterans Administration Hospital and Stanford University School of Medicine (Drs. Hollister and Shelton); Department of Neurology & Psychiatry, University of Texas Medical Branch, Galveston (Dr. Overall); Veterans Administration Hospital, Jackson, Miss (Dr. Pennington); Veterans Administration Hospital, Houston (Dr. Kimbell); and Veterans Administration Hospital and University of Washington School of Medicine, Seattle (Dr. Johnson).


Footnotes

Submitted for publication March 16, 1967.

Reprint requests to Veterans Administration Hospital, 3801 Junipero Serra Blvd, Palo Alto, Calif 94304 (Dr. Hollister).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1967 American Medical Association. All Rights Reserved.